Eli Lilly’s obesity pill will rival Novo Nordisk’s oral Wegovy drug

Eli LilyHis share is still recovering after the drug maker Train experimental data Earlier this month, on his close monitoring Obesity That is steeped in Wall Street.

In a major experience late in the stage, the ELI Lilly pill, Orforglipron caused weight loss and had higher side effects than analysts expected. It also seems that the effectiveness of the pill comes a little less than that Novo NordskOral Smaglutide for obesity, which showed strong data in a separate study.

The Eli Lilly shares have decreased about 13 % on the day the results of the experiment were released, although it has risen about 12 % since then.

But some analysts say that Eli Lili’s daily pill, if approved, can remain an applicable competitor in the space of weight loss – even if it is likely to be second to enter the market. It is a very profitable area keen on more convenient options that can reduce the lack of supply and access to obstacles created by the price of the weekly price that is currently dominated.

Analysts note that ELI Lilly pills can have some advantages on the daily oral version of Semaglutide for weight loss from Novo Nordisk, which goes on the right path to become The first alternative to the needle Even the obesity in the United States later this year. Elie Lily hopes Launching birth control pills “This time next year”, CEO David Rex told CNBC in early August.

Both drugs act by imitating the intestinal hormone called GLP-1 to suppress appetite and regulate blood sugar. But while Novo Nordisk is a drug for peptide, OrforiPron is a small molecular drug.

This means that ELI Lilly has been absorbed more easily in the body and does not require nutritional restrictions like Novo Nordisk. OrforiPron will also be easier to manufacture on a large scale, which is more important because the demand for obesity and diabetes injection exceeds the supply.

None of the companies have made prices for their birth control pills, but some analysts said that Eli Lily’s drug may have a lower price than Novo Nord’s pills. This will be a noticeable feature, as many health plans in the United States still cover obesity treatments.

“It is a little part of apples and oranges because Novo Nordisek may have difficulty manufacturing the product enough, given the high cost and requirements for manufacturing orally,” said David Rester, an analyst at Lerink, in an interview.

“Lily plans to install the world with, vaccine, or quickly generate great sales,” he continued. “It can be launched globally unusual with low prices and without considering eating.”

Goldman Sachs seems to agree, based on a note in August. They expect the daily overall pills to get 24 % – or about 22 billion dollars – from the global drug loss market 2030, which are expected to be worth 95 billion dollars.

Goldman analysts said they expect Eli Lily’s pills to have a 60 % stake – or nearly $ 13.6 billion – from the daily oral sector in the market in 2030. They expect to be a second degree from Novo Nordisk by mouth by 21 % – or about 4 billion dollars – from this section. Analysts said the remaining 19 % segment would go to other emerging pills.

The race to develop obesity pills was more suitable Vizar I had to scrap The former competitors and present that new. Novo Nordsik and Elie Lily also explores other experimental oral medications, along with a list of other companies such as Vicing treatmentsand Treatment structureand Astrazeneca and Rush.

“We strongly believe in the effectiveness” of the oral drug. The Danish company added that it will focus on the laser to obtain this product for patients without the supply restrictions “in the United States

Dr. Mihil “Misha” Zilbermint, director of the Endocrinology Hospital in Johns Hopkins Community Doctors, said it was difficult to win the winner between Eli Lily and Nofu Nordsik without knowing how their own pills will be priced and whether the insurance will cover them.

“I think that both drugs will be Gamechanics,” he said. “When it comes to the company that the game will win – the cost is the biggest problem.”

The Eli Lilly’s-1 experience also followed 3000 patients, while the Novo Nordisk’s Oasis 4 study was evaluated A much smaller group A spokesman for Novo Nordsek said that there are currently no directly comparable studies between the two medicines.

Oral SEMAGLUTIDE from Novo Nordisk seems to be a greater level of weight loss than ELI Lilly pills based on the available data, said Ivan Sigramman, an oral SEMAGLUTIDE from Novo Nordisk seems to cause a greater level of weight loss than ELI Lilly pills based on the available data.

In the experiment, the highest dose of ELI Lilly pills helped patients to lose 12.4 % of the average body weight in 72 weeks. Loss of weight in the pill was 11.2 % when analyzing all patients, regardless of stopping.

Wall Street was hoping to generate birth control pills in Eli Lily about 15 %, the same as the level of weight loss injection from Novo Nordsk. Semaglutide is the active ingredient in Wegovy and its OzemPic diabetes counterpart.

Meanwhile, the dose of the oral oral oral jacket from semaglutide by mouth from Novo Nordick helped patients to lose up to 16.6 % of their average weight in 64 weeks, according to the results of the experiment provided at a medical conference in 2024. This weight loss was 13.6 % when the company analyzed all patients regardless of whether they had stopped the medicine.

A spokesman for the Novo Nordisk added that 20 % of weight loss was observed in nearly a third of patients in the experiment.

However, the low effectiveness of Eli Lili pills may not be important enough to deter patients from taking them.

“For many patients, 12 % is a really large number,” Siggerman said. “There is definitely a market there,” for Orforglipron.

In a note earlier this month, Bank of America’s analysts shared similar feelings.

“Yes, weight loss has decreased slightly, but ask 100 of the qualities whether this new data will make a difference in those who put on the Glipron, and our faith is that the vast majority will say,” not really, “referring to the Eli Lilly experience.

Some investors have raised concerns about side effects and stopping rates in the trial of Eli Lily. But Seijerman said that the tolerance data for the drug – how it seems that patients are tolerant of them – seem relatively in line with the mouth by orally from Novo Nordisk.

About 10.3 % of patients who took the highest dose of ELI Lilly – 36 milligrams – stop treatment due to side effects, compared to about 2.6 % of those who took an imaginary drug.

These side effects were mainly the digestive system, such as nausea and vomiting, and light to moderate in severity. An estimated 24 % of those who received the highest dose of ELI Lilly to vomiting, while 33.7 % suffer from nausea.

Leerink’s Risiner said it is monitoring to know the stability of these intestinal problems that ELI Lilly shows full data.

The side effects of the experiment on Novo Nordsk pills were mostly related to the intestinal stomach: 30.9 % of those who took Smaglutide by mouth reporting vomiting and 46.6 % of nausea, according to the results of the experiment.

Johns Hopkins’ Zilbermint said it is difficult for anyone to decide with a better safety and endurance image based on the available data.

Meanwhile, Seigerman referred to a different factor “that would also matter a lot”: nutritional requirements.

He asked whether Novo Nordsk will tend to the deal recently concluded CVSPharmacy Director, Caremark. Under the deal, Caremark began to give priority to Novo Nordisk’s Wegovy for its standard drafting on July 1, making this weekly injection is the preferred GLP-1 of obesity on Zepbound.

But it is unclear whether orally can receive a similar preferential condition.

Seigerman also asked whether Eli Lilly would introduce Orforipron through its direct pharmacy to the consumer, Lillydirect. This offer exceeds insurance companies and pharmacy entitlements, allowing patients to buy zebound directly and some other ELI Lilly drugs from the company.

“This will be important.” This will be important.

For example, Viking Therapeutics on Tuesday Experimental data was issued in the middle of the stage disappointed Investors send their shares to up to 40 %.

Jared Halls, a strategic expert in Mimuho’s health care shares, said in an e -mail on Tuesday that the results of Viking “seemed less inferior” for those of Eli Lily’s pills “on almost all standards.”

Viking pills once daily helped patients lose up to 12.2 % of their weight in about three months, with no plateau, which means that patients may lose more in a long -term study.

Hulls pointed to the high rate of patients who stopped the Viking drug for any reason for 13 weeks, which was about 28 %. Meanwhile, about a quarter of people have stopped ELI Lilly, or Forlingglipron, for any reason for 72 weeks.

This “is a much longer trial and thus [Lilly] “It looks much better face to face,” Hulls said.